$TCRT
Alaunos Therapeutics, Inc.

2018 Q3 Form 10-Q Financial Statement

#000119312518242705 Filed on August 08, 2018

View on sec.gov

Income Statement

Concept 2018 Q3 2018 Q2 2017 Q2
Revenue $0.00 $0.00 $1.597M
YoY Change -100.0% -100.0% -6.06%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.310M $4.890M $3.780M
YoY Change 20.73% 29.37% 1.89%
% of Gross Profit
Research & Development $8.263M $7.489M $10.83M
YoY Change -25.59% -30.86% -91.62%
% of Gross Profit
Depreciation & Amortization $150.0K $140.0K $90.00K
YoY Change 66.67% 55.56% 0.0%
% of Gross Profit
Operating Expenses $12.57M $12.38M $10.83M
YoY Change 13.19% 14.28% -91.62%
Operating Profit -$12.57M -$12.38M -$13.01M
YoY Change -3.88% -4.89% -90.08%
Interest Expense -$170.0K $180.0K $70.00K
YoY Change -185.0% 157.14%
% of Operating Profit
Other Income/Expense, Net $150.0K $164.0K $86.00K
YoY Change -14.29% 90.7% 104.76%
Pretax Income -$12.59M -$12.03M -$12.86M
YoY Change -0.87% -6.45% -90.2%
Income Tax
% Of Pretax Income
Net Earnings -$18.66M -$17.49M -$17.73M
YoY Change 5.99% -1.32% -86.49%
Net Earnings / Revenue -1110.02%
Basic Earnings Per Share -$0.13 -$0.12
Diluted Earnings Per Share -$0.13 -$0.12 -$0.13
COMMON SHARES
Basic Shares Outstanding 142.4M shares 142.4M shares 132.4M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q3 2018 Q2 2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $31.70M $40.40M $97.20M
YoY Change -62.44% -58.44% -10.83%
Cash & Equivalents $31.73M $40.40M $97.19M
Short-Term Investments
Other Short-Term Assets $14.40M $11.90M $27.90M
YoY Change -52.79% -57.35% 57.63%
Inventory
Prepaid Expenses
Receivables $1.000M $700.0K $0.00
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $47.16M $52.99M $125.1M
YoY Change -58.95% -57.65% -1.25%
LONG-TERM ASSETS
Property, Plant & Equipment $1.344M $1.332M $1.062M
YoY Change 28.37% 25.42% 55.72%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $18.17M $21.93M $493.0K
YoY Change 3562.9% 4348.28% 0.0%
Total Long-Term Assets $19.64M $23.39M $1.683M
YoY Change 1075.34% 1289.78% 29.16%
TOTAL ASSETS
Total Short-Term Assets $47.16M $52.99M $125.1M
Total Long-Term Assets $19.64M $23.39M $1.683M
Total Assets $66.80M $76.38M $126.8M
YoY Change -42.69% -39.77% -0.94%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.269M $588.0K $81.00K
YoY Change -16.73% 625.93% -96.01%
Accrued Expenses $9.377M $8.663M $9.354M
YoY Change -7.25% -7.39% 26.54%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $60.18M $9.314M $15.99M
YoY Change 230.88% -41.74% -0.29%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $2.600M $51.90M $40.90M
YoY Change -93.35% 26.89% -8.91%
Total Long-Term Liabilities $2.600M $51.90M $40.90M
YoY Change -93.35% 26.89% -75.05%
TOTAL LIABILITIES
Total Short-Term Liabilities $60.18M $9.314M $15.99M
Total Long-Term Liabilities $2.600M $51.90M $40.90M
Total Liabilities $62.79M $61.19M $56.85M
YoY Change 9.6% 7.63% -68.42%
SHAREHOLDERS EQUITY
Retained Earnings -$761.2M -$748.6M -$686.5M
YoY Change 8.87% 9.05% 7.95%
Common Stock $604.8M $609.4M $622.2M
YoY Change -2.35% -2.06% 6.55%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$156.4M -$139.2M -$64.27M
YoY Change
Total Liabilities & Shareholders Equity $66.80M $76.38M $126.8M
YoY Change -42.69% -39.77% -0.94%

Cashflow Statement

Concept 2018 Q3 2018 Q2 2017 Q2
OPERATING ACTIVITIES
Net Income -$18.66M -$17.49M -$17.73M
YoY Change 5.99% -1.32% -86.49%
Depreciation, Depletion And Amortization $150.0K $140.0K $90.00K
YoY Change 66.67% 55.56% 0.0%
Cash From Operating Activities -$8.510M -$10.17M -$15.52M
YoY Change -33.04% -34.47% 2.99%
INVESTING ACTIVITIES
Capital Expenditures $170.0K $230.0K $30.00K
YoY Change 142.86% 666.67% -70.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$170.0K -$230.0K -$30.00K
YoY Change 142.86% 666.67% -70.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 -310.0K 46.30M
YoY Change -100.67% -7010.45%
NET CHANGE
Cash From Operating Activities -8.510M -10.17M -15.52M
Cash From Investing Activities -170.0K -230.0K -30.00K
Cash From Financing Activities 0.000 -310.0K 46.30M
Net Change In Cash -8.680M -10.71M 30.75M
YoY Change -32.08% -134.83% -294.13%
FREE CASH FLOW
Cash From Operating Activities -$8.510M -$10.17M -$15.52M
Capital Expenditures $170.0K $230.0K $30.00K
Free Cash Flow -$8.680M -$10.40M -$15.55M
YoY Change -32.08% -33.12% 2.5%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q1 ziop Sharebased Compensation Arrangement By Sharebased Payment Award Option Having Contractual Life Extended
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionHavingContractualLifeExtended
751667 shares
CY2018Q1 ziop Sharebased Compensation Arrangement By Sharebased Payment Award Option Having Contractual Life Extended
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionHavingContractualLifeExtended
117500 shares
CY2018Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
142379770 shares
CY2017Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
97194000
CY2017Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
97582000
CY2017Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
388000
CY2018Q1 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
2469000
CY2018Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
588000
CY2018Q2 us-gaap Assets
Assets
76383000
CY2018Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8663000
CY2018Q2 us-gaap Assets Current
AssetsCurrent
52993000
CY2018Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
609247000
CY2018Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
40404000
CY2018Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
40793000
CY2018Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2018Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
142379770 shares
CY2018Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
142379770 shares
CY2018Q2 us-gaap Common Stock Value
CommonStockValue
142000
CY2018Q2 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
5000
CY2018Q2 us-gaap Deferred Rent Credit
DeferredRentCredit
68000
CY2018Q2 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
2358000
CY2018Q2 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
63000
CY2018Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
49513000
CY2018Q2 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
128000
CY2018Q2 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
2358000
CY2018Q2 us-gaap Liabilities
Liabilities
61190000
CY2018Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
76383000
CY2018Q2 us-gaap Liabilities Current
LiabilitiesCurrent
9314000
CY2018Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
21930000
CY2018Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000 shares
CY2018Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11926000
CY2018Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
389000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4417000
CY2017Q4 us-gaap Assets
Assets
105606000
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9909000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
90783000
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
615493000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
70946000
CY2018Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
0
CY2018Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1332000
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
318961 shares
CY2018Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-748624000
CY2018Q2 us-gaap Receivables Net Current
ReceivablesNetCurrent
663000
CY2018Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
415000
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
415000
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2840835 shares
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.97
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3803802 shares
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.08
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
-139235000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
81441000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
71335000
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
142658037 shares
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
142658037 shares
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
143000
CY2017Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1000
CY2017Q4 us-gaap Deferred Rent Credit
DeferredRentCredit
142000
CY2017Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
6389000
CY2017Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
2424000
CY2017Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
141000
CY2017Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
35139000
CY2017Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
128000
CY2017Q4 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
2424000
CY2017Q4 us-gaap Liabilities
Liabilities
58420000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
105606000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
20856000
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
13484000
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000 shares
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
19818000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1211000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-712442000
CY2017Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
19000
CY2017Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1152000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2925502 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.12
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3852135 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.12
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
-96806000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
28157585 shares
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
16141000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-1494000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
167000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.28
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-3194000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7375000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-75000
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-65000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4083000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
23000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
246000
us-gaap Interest Paid Net
InterestPaidNet
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-385000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
46326000
us-gaap Payments For Repurchase Of Equity
PaymentsForRepurchaseOfEquity
1042000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-37385000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29800000
us-gaap Net Income Loss
NetIncomeLoss
-28349000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
124000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
385000
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
30173000
us-gaap Operating Income Loss
OperatingIncomeLoss
-26979000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
367000
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
9036000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
98000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
47270000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.45
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3194000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22798000
us-gaap Share Based Compensation
ShareBasedCompensation
4082000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
265500 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
133176934 shares
dei Amendment Flag
AmendmentFlag
false
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
47256724 shares
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5370000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-30542000
us-gaap Cumulative Effect On Retained Earnings Net Of Tax1
CumulativeEffectOnRetainedEarningsNetOfTax1
-8131000
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
211000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
255000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.27
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
dei Document Type
DocumentType
10-Q
us-gaap Dividends Preferred Stock
DividendsPreferredStock
10582000
dei Entity Registrant Name
EntityRegistrantName
ZIOPHARM ONCOLOGY INC
dei Entity Central Index Key
EntityCentralIndexKey
0001107421
dei Document Period End Date
DocumentPeriodEndDate
2018-06-30
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-146000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
8447000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11048000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3829000
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-74000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29131000
us-gaap Net Income Loss
NetIncomeLoss
-28051000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
312000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
376000
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
28720000
us-gaap Operating Income Loss
OperatingIncomeLoss
-28574000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
389000
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
10582000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
240000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-7892000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
645000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1245000
us-gaap Interest Paid Net
InterestPaidNet
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-376000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1035000
us-gaap Payments For Repurchase Of Equity
PaymentsForRepurchaseOfEquity
1275000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-38633000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y1M27D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
149666 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.06
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
146000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
146000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17672000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
5.50
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.32
us-gaap Share Based Compensation
ShareBasedCompensation
5370000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y1M20D
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.30
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
240000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
205500 shares
us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
1275000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
205500 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
140935964 shares
dei Trading Symbol
TradingSymbol
ZIOP
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
104167 shares
us-gaap Stock Issued During Period Value Restricted Stock Award Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
0
ziop Additional Share Based Compensation Expense
AdditionalShareBasedCompensationExpense
481000
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y6M29D
CY2018Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
28000
CY2018Q1 ziop Embedded Derivative Dividend Amount
EmbeddedDerivativeDividendAmount
73000
CY2017Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
66000
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.13
CY2017Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3780000
CY2017Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17727000
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-12862000
CY2017Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
86000
CY2017Q2 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
14611000
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-13014000
CY2017Q2 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
196000
CY2017Q2 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
4865000
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.8093 pure
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0185 pure
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.48
CY2017Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1597000
CY2017Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10831000
CY2017Q2 us-gaap Share Based Compensation
ShareBasedCompensation
2058000
CY2017Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.8103 pure
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
148500 shares
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0205 pure
CY2017Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
135630210 shares
CY2018Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
183000
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.12
CY2018Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4889000
CY2018Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17493000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-12031000
CY2018Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
164000
CY2018Q2 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
12378000
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-12378000
CY2018Q2 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
213000
CY2018Q2 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
5462000
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.8148 pure
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0266 pure
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.06
CY2018Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7489000
CY2018Q2 us-gaap Share Based Compensation
ShareBasedCompensation
1711000
CY2018Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.8166 pure
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
198000 shares
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0291 pure
CY2018Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
141017898 shares
CY2018Q2 ziop Embedded Derivative Dividend Amount
EmbeddedDerivativeDividendAmount
72000
CY2018Q2 ziop Additional Share Based Compensation Expense
AdditionalShareBasedCompensationExpense
481000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
40000

Files In Submission

Name View Source Status
0001193125-18-242705-index-headers.html Edgar Link pending
0001193125-18-242705-index.html Edgar Link pending
0001193125-18-242705.txt Edgar Link pending
0001193125-18-242705-xbrl.zip Edgar Link pending
d543555d10q.htm Edgar Link pending
d543555dex311.htm Edgar Link pending
d543555dex312.htm Edgar Link pending
d543555dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ziop-20180630.xml Edgar Link completed
ziop-20180630.xsd Edgar Link pending
ziop-20180630_cal.xml Edgar Link unprocessable
ziop-20180630_def.xml Edgar Link unprocessable
ziop-20180630_lab.xml Edgar Link unprocessable
ziop-20180630_pre.xml Edgar Link unprocessable